女性生殖道和肠道微生物在卵巢癌中的研究进展

doi:10.12280/gjfckx.20210724

摘要/Abstract

摘要：

卵巢癌致死率极高,但发病机制尚不清楚。近年随着高通量测序技术的发展,女性生殖道和肠道微生物在卵巢癌方面的研究已成为热点。研究发现,在卵巢癌中,上、下生殖道优势菌群厚壁杆菌丰度降低,拟杆菌数量增多,肠道菌群频繁失调。其可能通过自身成分和代谢产物引起致癌反应、升高循环中的雌激素水平、促进卵巢癌发生,介导炎症反应影响免疫调节,在卵巢癌的发生发展中起重要作用。此外,女性生殖道和肠道微生物群还参与卵巢癌的治疗过程,与耐药和疗效密切相关。其中,粪菌移植、益生菌补充及抗生素的应用已得到初步探索。综述女性生殖道和肠道微生物群结构、与卵巢癌的相关性以及临床治疗研究,旨在为卵巢癌的筛查、治疗及预防提供新的方向和策略。

关键词: 卵巢肿瘤, 生殖道感染, 微生物群, 胃肠道微生物组, 免疫, 抗药性, 微生物

Abstract:

The mortality rate of ovarian cancer is very high, but the pathogenesis is still unclear. In recent years, with the development of high-throughput sequencing technologies, the study of the female reproductive tract and gut microbiome in ovarian cancer has become a hot spot. It was found that in ovarian cancer, the abundance of firmicutes in the upper and lower reproductive tract decreased, the number of bacteroides increased and the gut microbiome was often dysbiosis. It may play an important role in the development of ovarian cancer by causing carcinogenic reactions through its components and metabolites, increasing the ratio of estrogen to promote ovarian carcinogenesis, and mediating inflammatory responses that affect immune regulation. In addition, the female reproductive tract and gut microbiome are involved in the therapeutic process of ovarian cancer and are closely associated with drug resistance and efficacy. Among these, fecal transplantation, probiotic supplementation, and antibiotic application have been initially explored. This article focuses on the structure of the female reproductive tract and gut microbiome, its relevance to ovarian cancer, and clinical treatment studies, to provide new directions and strategies for the screening, treatment, and prevention of ovarian cancer.

Key words: Ovarian neoplasms, Reproductive tract infections, Microbiota, Gastrointestinal microbiome, Immunity, Drug resistance, microbial

郭文迪, 平毅. 女性生殖道和肠道微生物在卵巢癌中的研究进展[J]. 国际妇产科学杂志, 2022, 49(1): 29-33.

GUO Wen-di, PING Yi. Research Progress of Female Reproductive Tract and Gut Microbiome in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 29-33.

参考文献 40

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Jacobson D, Moore K, Gunderson C, et al. Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer[J]. PeerJ, 2021, 9:e11574. doi: 10.7717/peerj.11574. doi: 10.7717/peerj.11574 pmid: 34178459
[3]	Idahl A, Le Cornet C, González Maldonado S, et al. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort[J]. Int J Cancer, 2020, 147(8):2042-2052. doi: 10.1002/ijc.32999. doi: 10.1002/ijc.32999
[4]	Nené NR, Reisel D, Leimbach A, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study[J]. Lancet Oncol, 2019, 20(8):1171-1182. doi: 10.1016/S1470-2045(19)30340-7. doi: 10.1016/S1470-2045(19)30340-7
[5]	Cheng H, Wang Z, Cui L, et al. Opportunities and Challenges of the Human Microbiome in Ovarian Cancer[J]. Front Oncol, 2020, 10:163. doi: 10.3389/fonc.2020.00163. doi: 10.3389/fonc.2020.00163
[6]	Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study[J]. Lancet Oncol, 2011, 12(9):900-904. doi: 10.1016/S1470-2045(11)70165-6. doi: 10.1016/S1470-2045(11)70165-6
[7]	Trabert B, Waterboer T, Idahl A, et al. Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations[J]. J Natl Cancer Inst, 2019, 111(2):129-136. doi: 10.1093/jnci/djy084. doi: 10.1093/jnci/djy084
[8]	Wang Q, Zhao L, Han L, et al. The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ[J]. J Ovarian Res, 2020, 13(1):8. doi: 10.1186/s13048-019-0603-4. doi: 10.1186/s13048-019-0603-4 pmid: 31954395
[9]	Xu S, Liu Z, Lv M, et al. Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer[J]. Pathog Dis, 2019, 77(2):ftz019. doi: 10.1093/femspd/ftz019. doi: 10.1093/femspd/ftz019
[10]	Miao R, Badger TC, Groesch K, et al. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer[J]. PLoS One, 2020, 15(1):e0227707. doi: 10.1371/journal.pone.0227707. doi: 10.1371/journal.pone.0227707
[11]	Park GB, Chung YH, Kim D. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells[J]. Oncol Rep, 2017, 37(5):3137-3145. doi: 10.3892/or.2017.5533. doi: 10.3892/or.2017.5533 pmid: 28350104
[12]	Xie H, Hou Y, Cheng J, et al. Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer[J]. Oncotarget, 2017, 8(19):32134-32146. doi: 10.18632/oncotarget.16739. doi: 10.18632/oncotarget.16739
[13]	Sonner JK, Keil M, Falk-Paulsen M, et al. Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology[J]. Nat Commun, 2019, 10(1):4877. doi: 10.1038/s41467-019-12776-4. doi: 10.1038/s41467-019-12776-4 pmid: 31653831
[14]	Raza MH, Gul K, Arshad A, et al. Microbiota in cancer development and treatment[J]. J Cancer Res Clin Oncol, 2019, 145(1):49-63. doi: 10.1007/s00432-018-2816-0. doi: 10.1007/s00432-018-2816-0
[15]	Trabert B, Coburn SB, Falk RT, et al. Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women′s Health Initiative Observational Study[J]. Cancer Causes Control, 2019, 30(11):1201-1211. doi: 10.1007/s10552-019-01233-8. doi: 10.1007/s10552-019-01233-8
[16]	Fuhrman BJ, Feigelson HS, Flores R, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women[J]. J Clin Endocrinol Metab, 2014, 99(12):4632-4640. doi: 10.1210/jc.2014-2222. doi: 10.1210/jc.2014-2222
[17]	Parida S, Sharma D. The Microbiome-Estrogen Connection and Breast Cancer Risk[J]. Cells, 2019, 8(12):1642. doi: 10.3390/cells8121642. doi: 10.3390/cells8121642
[18]	Smolková K, Mikó E, Kovács T, et al. Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism[J]. Antioxid Redox Signal, 2020, 33(13):966-997. doi: 10.1089/ars.2020.8024. doi: 10.1089/ars.2020.8024
[19]	Rahbar Saadat Y, Pourseif MM, Zununi Vahed S, et al. Modulatory Role of Vaginal-Isolated Lactococcus lactis on the Expression of miR-21, miR-200b, and TLR-4 in CAOV-4 Cells and In Silico Revalidation[J]. Probiotics Antimicrob Proteins, 2020, 12(3):1083-1096. doi: 10.1007/s12602-019-09596-9. doi: 10.1007/s12602-019-09596-9 pmid: 31797280
[20]	Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer[J]. Oncogene, 2009, 28(49):4353-4363. doi: 10.1038/onc.2009.289. doi: 10.1038/onc.2009.289 pmid: 19826413
[21]	Browning L, Patel MR, Horvath EB, et al. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis[J]. Cancer Manag Res, 2018, 10:6685-6693. doi: 10.2147/CMAR.S179189. doi: 10.2147/CMAR.S179189 pmid: 30584363
[22]	Park GB, Kim D. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression[J]. Oncol Rep, 2017, 38(5):3167-3176. doi: 10.3892/or.2017.5941. doi: 10.3892/or.2017.5941 pmid: 28901470
[23]	Rutkowski MR, Stephen TL, Svoronos N, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation[J]. Cancer Cell, 2015, 27(1):27-40. doi: 10.1016/j.ccell.2014.11.009. doi: 10.1016/j.ccell.2014.11.009 pmid: 25533336
[24]	Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress[J]. Clin Epigenetics, 2019, 11(1):7. doi: 10.1186/s13148-018-0602-0. doi: 10.1186/s13148-018-0602-0 pmid: 30646939
[25]	Allavena P, Chieppa M, Bianchi G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages[J]. Clin Dev Immunol, 2010, 2010:547179. doi: 10.1155/2010/547179. doi: 10.1155/2010/547179
[26]	Zandi Z, Kashani B, Poursani EM, et al. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition[J]. Eur J Pharmacol, 2019, 853:256-263. doi: 10.1016/j.ejphar.2019.03.046. doi: 10.1016/j.ejphar.2019.03.046
[27]	Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science, 2013, 342(6161):967-970. doi: 10.1126/science.1240527. doi: 10.1126/science.1240527
[28]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371):91-97. doi: 10.1126/science.aan3706. doi: 10.1126/science.aan3706
[29]	Perales-Puchalt A, Perez-Sanz J, Payne KK, et al. Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy[J]. J Leukoc Biol, 2018, 103(5):799-805. doi: 10.1002/JLB.5HI1117-446RR. doi: 10.1002/JLB.5HI1117-446RR
[30]	Wang Y, Sun L, Chen S, et al. The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice[J]. Life Sci, 2019, 231:116529. doi: 10.1016/j.lfs.2019.06.004. doi: 10.1016/j.lfs.2019.06.004
[31]	Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota[J]. Oncoimmunology, 2016, 5(6):e1150399. doi: 10.1080/2162402X.2016.1150399. doi: 10.1080/2162402X.2016.1150399
[32]	Davar D, Dzutsev AK, Mcculloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J]. Science, 2021, 371(6529):595-602. doi: 10.1126/science.abf3363. doi: 10.1126/science.abf3363
[33]	Zhou B, Xia M, Wang B, et al. Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo[J]. J Ovarian Res, 2019, 12(1):107. doi: 10.1186/s13048-019-0570-9. doi: 10.1186/s13048-019-0570-9 pmid: 31703731
[34]	Michalak M, Lach MS, Antoszczak M, et al. Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study[J]. Molecules, 2020, 25(3):537. doi: 10.3390/molecules25030537. doi: 10.3390/molecules25030537
[35]	Chambers LM, Kuznicki M, Yao M, et al. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer[J]. Gynecol Oncol, 2020, 159(3):699-705. doi: 10.1016/j.ygyno.2020.09.010. doi: 10.1016/j.ygyno.2020.09.010 pmid: 32950250
[36]	Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat Med, 2004, 10(9):942-949. doi: 10.1038/nm1093. doi: 10.1038/nm1093 pmid: 15322536
[37]	Schepisi G, Casadei C, Toma I, et al. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy[J]. Cancers(Basel), 2021, 13(4):840. doi: 10.3390/cancers13040840. doi: 10.3390/cancers13040840
[38]	Zhang X, He T, Li Y, et al. Dendritic Cell Vaccines in Ovarian Cancer[J]. Front Immunol, 2020, 11:613773. doi: 10.3389/fimmu.2020.613773. doi: 10.3389/fimmu.2020.613773 pmid: 33584699
[39]	Wallace TC, Bultman S, D′Adamo C, et al. Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting[J]. J Am Coll Nutr, 2019, 38(1):1-14. doi: 10.1080/07315724.2018.1500499. doi: 10.1080/07315724.2018.1500499 pmid: 30511901
[40]	Playdon MC, Nagle CM, Ibiebele TI, et al. Pre-diagnosis diet and survival after a diagnosis of ovarian cancer[J]. Br J Cancer, 2017, 116(12):1627-1637. doi: 10.1038/bjc.2017.120. doi: 10.1038/bjc.2017.120